Noninvasive prognostic biomarker potential of quantifying the propeptides of <scp>Type XI</scp> collagen alpha‐1 chain ( <scp>PRO‐C11</scp> ) in patients with pancreatic ductal adenocarcinoma

Type XI collagen has been associated with tumor fibrosis and aggressiveness in patients pancreatic ductal adenocarcinoma (PDAC). The propeptide on is released into the circulation after proteolytic processing at either amino acid 253 or 511. This allows for a noninvasive biomarker approach to quantify production. We developed two ELISA-based biomarkers, targeting enzymatic cleavage sites (PRO-C11-253 PRO-C11-511). In discovery cohort including serum from PDAC (n = 39, Stages 1-4), chronic pancreatitis (CP, n 12) healthy controls 20), PRO-C11-511, but not PRO-C11-253, was significantly upregulated CP compared controls. Furthermore, PRO-C11-511 levels >75th percentile were poor overall survival (OS) (HR, 95% CI: 3.40, 1.48-7.83). potential validated 686 PDAC. Again, high of (>75th percentile) OS 1.68, 1.40-2.02). remained significant adjusting clinical risk factors 1.50, 1.22-1.86). conclusion, quantifying predicts supports that important biology prognostic